Investigative Agents
According to a 2001 article, of the nearly 500 cancer drugs currently in development, 58 of them (about 13%) are aimed at fighting lung cancer. (Only the number of breast cancer drugs exceeded that percentage.) Unfortunately, none to date have shown any significant impact on patient survival. Still, some are showing promise, and at this time these agents are best hope for improving lung cancer survival rates.
Monoclonal Antibodies (MAbs)
Text Continues Below
Monoclonal antibodies (MAbs) are genetically designed immune factors that target foreign compounds called antigens for attack by the immune system. Trastuzumab (Herceptin), cetuximab (Erbitux), and bevacizumab (Avastin) are MAbs that block epidermal growth factor are under investigation. These agents are of particular interest for patients who have cancers that overexpress a protein called HER2. Trials showing some promise employ these agents in combination with chemotherapies and newer drugs, such as the tyrosine kinase inhibitor.
Antisense Oligonucleotide
Antisense oligonucleotides are drugs that are being used to block molecules that result in genetically overexpressed cells that cause cancers. LY900003 (Affinitak), for example, targets an enzyme called PKC-alpha, which promotes tumor growth. Early studies showed some promising results although a 2003 study found no difference in effectiveness when used in combination with platinum-based chemotherapy compared to the chemotherapy alone.
Oblimersen (G3139) blocks BCL-2, another protein that is genetically overexpressed in some cancers, is also under investigation.
Genetic Therapy
.gif)
